Tarsus posts $194.6 million in XDEMVY sales, advances four-drug pipeline

Tarsus Pharmaceuticals reported third quarter 2026 results on November 3, 2026, covering the period ended September 30, 2026. XDEMVY generated third quarter 2026 net product sales of $194.6 million, a year-over-year increase of approximately 64%.¹ The company said the drug has passed one million bottles dispensed and $1 billion in cumulative net sales since launch, calling it the only FDA-approved treatment for Demodex blepharitis.¹

On the pipeline, Tarsus gave updated timing for four programs. The Phase 2 Kore trial of TP-04 for ocular rosacea is continuing, with topline data expected in the first half of 2027.¹ Enrollment is complete in the Phase 2 Calliope trial of TP-05 for Lyme disease prevention, with topline results expected in the first half of 2027 that the company said are meant to support a Phase 3-ready package.¹ For IRX-101, the company plans to start the Phase 3 Comfort study of an investigational ocular antiseptic for patients receiving intravitreal injections in the first half of 2027, with topline results expected in 2028.¹ Enrollment is ongoing in the global Phase 3 Northstar trial of gildeuretinol for Stargardt disease, with topline results now expected in 2029.¹

The quarter also included corporate changes. Tarsus completed its acquisitions of iRenix Medical, which brought IRX-101, and Alkeus Pharmaceuticals, which brought gildeuretinol.¹ The company appointed Neera Clase as Chief Commercial Officer, citing her prior role in building the XDEMVY commercial team and securing coverage.¹

On the balance sheet, cash, cash equivalents and marketable securities totaled $309.6 million as of September 30, 2026.¹ Acquired in-process R&D expense of $632.2 million for the quarter reflected the acquisition-date fair values assigned to the IRX-101 and gildeuretinol programs, which the company expensed immediately because they had no alternative use.¹ Net loss for the quarter was $668.3 million, compared with $12.6 million a year earlier.¹